OMER Share Price Performance
US$11.93
8.06 (208.27%)
63.8% undervalued intrinsic discount
US$33.00
Fair Value
Price US$11.93
AnalystConsensusTarget US$33.00
AnalystHighTarget US$40.00
Fair ValueUS$33.00
Share Pricen/a
Seeking Alpha • Jul 07
Omeros Corporation Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
OMER Community Narratives
AN
Fair Value
·Fair Value US$33 63.8% undervalued intrinsic discount
Complement Platform And Novo Nordisk Deal Will Reshape Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$40 70.2% undervalued intrinsic discount
Lectin Pathway Platform And Pipeline Will Transform Rare Disease Treatment Over The Coming Years
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Complement Platform And Novo Nordisk Deal Will Reshape Long Term Outlook
A major deal with Novo Nordisk could give Omeros breathing room and more time to push its next medicines forward, reshaping what the company looks like over the next few years. The big question is whether its lead transplant-related treatment clears regulators and gains real-world use before cash and development risks catch up.Read more
AN
US$33
63.8% undervalued intrinsic discount
Fair Value
Revenue
211.11% p.a.
Profit Margin
7.98%
Future PE
148.42x
Price in 2029
US$40.53
Lectin Pathway Platform And Pipeline Will Transform Rare Disease Treatment Over The Coming Years
Omeros has a newly launched drug that’s already gaining traction in a rare, high-need condition, and it could become the go-to option as hospitals get clearer ways to pay for it. The bigger story is whether this one launch can open the door to more uses, new countries, and a deeper pipeline—or whether competition, slow adoption, and funding needs get in the way.Read more
AN
US$40
70.2% undervalued intrinsic discount
Fair Value
Revenue
393.25% p.a.
Profit Margin
55.98%
Future PE
6.44x
Price in 2029
US$49.15
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
OMER: I Expect EMA Reexamination On TA TMA Therapy Will Unlock Upside
Fair Value: US$33 63.8% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Lectin Pathway Platform And Pipeline Will Transform Rare Disease Treatment Over The Coming Years
Fair Value: US$40 70.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Omeros Corporation Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 1.16
- -190.49%
- 849.15%
- -338.8%
About OMER
- Founded
- 1994
- Employees
- 175
- CEO
- WebsiteView website
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
